Image may be NSFW.
Clik here to view.
Drug osimertinib has been approved by FDA for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, revealed a clinical trial led by Yale Cancer Center (YCC) researchers. NSCLC occurs in about 10 percent of patients.
The benefit of osimertinib treatment was so substantial during the ADAURA trial that the independent data monitoring committee recommended early unblinding of the multinational randomized controlled phase III trial to make the data ...
Clik here to view.
Drug osimertinib has been approved by FDA for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, revealed a clinical trial led by Yale Cancer Center (YCC) researchers. NSCLC occurs in about 10 percent of patients.
The benefit of osimertinib treatment was so substantial during the ADAURA trial that the independent data monitoring committee recommended early unblinding of the multinational randomized controlled phase III trial to make the data ...
